Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous,... Purpose Fosaprepitant improved prevention of chemotherapy-induced nausea and vomiting (CINV) in a randomized, double- blind phase III trial (PN031). This post hoc analysis explored factors that may have influenced response. Methods Adult subjects (N = 1000) scheduled to receive non-anthracycline and cyclophosphamide (AC) moderately emetogenic chemotherapy (MEC) on day 1 were randomly assigned 1:1 to a single-dose, 150-mg intravenous fosaprepitant regimen or a control regimen. Both regimens included dexamethasone and ondansetron on day 1, with ondansetron continuing through day 3 in the control arm only. Complete response (CR; no vomiting and no rescue medication) rates in the acute, delayed, and overall phases (0–25, 25–120, and 0–120 h, respectively) were analyzed by chemotherapy type (carboplatin-based vs non-carboplatin- based), chemotherapy duration (single-day vs multiple-day), and baseline characteristics. Results Most subjects received single-day chemotherapeutic regimens (70.6%), which were mainly carboplatin-based (67.6%). CR with fosaprepitant was consistent (76–80%) during the delayed and overall phases in carboplatin-based and non-carboplatin- based subgroups and in subgroups receiving single-day or multiple-day MEC regimens. Treatment effects favored fosaprepitant for the carboplatin-based versus the non-carboplatin-based group during the delayed phase (14.1 vs 6.5%; p =0.06), and for the single-day versus the multiple-day subgroup during the delayed (13.2 vs 3.2%; http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Supportive Care in Cancer Springer Journals

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

Loading next page...
 
/lp/springer_journal/evaluation-of-factors-contributing-to-the-response-to-fosaprepitant-in-ylRoLeM0q1
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine
ISSN
0941-4355
eISSN
1433-7339
D.O.I.
10.1007/s00520-018-4242-x
Publisher site
See Article on Publisher Site

Abstract

Purpose Fosaprepitant improved prevention of chemotherapy-induced nausea and vomiting (CINV) in a randomized, double- blind phase III trial (PN031). This post hoc analysis explored factors that may have influenced response. Methods Adult subjects (N = 1000) scheduled to receive non-anthracycline and cyclophosphamide (AC) moderately emetogenic chemotherapy (MEC) on day 1 were randomly assigned 1:1 to a single-dose, 150-mg intravenous fosaprepitant regimen or a control regimen. Both regimens included dexamethasone and ondansetron on day 1, with ondansetron continuing through day 3 in the control arm only. Complete response (CR; no vomiting and no rescue medication) rates in the acute, delayed, and overall phases (0–25, 25–120, and 0–120 h, respectively) were analyzed by chemotherapy type (carboplatin-based vs non-carboplatin- based), chemotherapy duration (single-day vs multiple-day), and baseline characteristics. Results Most subjects received single-day chemotherapeutic regimens (70.6%), which were mainly carboplatin-based (67.6%). CR with fosaprepitant was consistent (76–80%) during the delayed and overall phases in carboplatin-based and non-carboplatin- based subgroups and in subgroups receiving single-day or multiple-day MEC regimens. Treatment effects favored fosaprepitant for the carboplatin-based versus the non-carboplatin-based group during the delayed phase (14.1 vs 6.5%; p =0.06), and for the single-day versus the multiple-day subgroup during the delayed (13.2 vs 3.2%;

Journal

Supportive Care in CancerSpringer Journals

Published: May 28, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off